Cargando…

A double blind randomized trial of wound infiltration with ropivacaine after breast cancer surgery with axillary nodes dissection

BACKGROUND: The effect of local infiltration after breast surgery is controversial. This prospective double blind randomized study sought to document the analgesic effect of local anaesthetic infiltration after breast cancer surgery. METHODS: Patients scheduled for mastectomy or tumorectomy and axil...

Descripción completa

Detalles Bibliográficos
Autores principales: Vigneau, Axelle, Salengro, Anne, Berger, Joelle, Rouzier, Roman, Barranger, Emmanuel, Marret, Emmanuel, Bonnet, Francis
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2011
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3239295/
https://www.ncbi.nlm.nih.gov/pubmed/22114900
http://dx.doi.org/10.1186/1471-2253-11-23
Descripción
Sumario:BACKGROUND: The effect of local infiltration after breast surgery is controversial. This prospective double blind randomized study sought to document the analgesic effect of local anaesthetic infiltration after breast cancer surgery. METHODS: Patients scheduled for mastectomy or tumorectomy and axillary nodes dissection had immediate postoperative infiltration of the surgical wound with 20 ml of ropivacaine 7.5 mg.ml(-1 )or isotonic saline. Pain was assessed on a visual analogue scale at H2, H4, H6, H12, H24, H72, and at 2 month, at rest and on mobilization of the arm. Patient'comfort was evaluated with numerical 0-3 scales for fatigue, quality of sleep, state of mood, social function and activity. RESULTS: Twenty-two and 24 patients were included in the ropivacaine and saline groups respectively. Postoperative pain was lower at rest and on mobilization at 2, 4 and 6 hour after surgery in the ropivacaine group. No other difference in pain intensity and patient 'comfort scoring was documented during the first 3 postoperative days. Patients did not differ at 2 month for pain and comfort scores. CONCLUSION: Single shot infiltration with ropivacaine transiently improves postoperative pain control after breast cancer surgery. TRIAL REGISTRATION NUMBER: NCT01404377